Liver, Gallbladder, and Biliary Tract Cancers

Liver, Gallbladder, and Biliary Tract Cancers

The addition of cediranib to treatment with cisplatin/gemcitabine did not improve progression-free survival in patients with advanced biliary tract cancer, according to the results of the phase II ABC-03 trial.

Treatment with sorafenib after curative resection or ablation of hepatocellular carcinoma did not improve recurrence-free survival compared with placebo, according to the results of the phase III STORM trial.

A meta-analysis of over 15,000 patients with liver cirrhosis who were diagnosed with hepatocellular carcinoma demonstrates the benefit of screening these patients for liver tumors.

A 65-year-old woman with rheumatoid arthritis and autoimmune hepatitis presented to clinic for evaluation of a liver mass. Six months prior to presentation, workup was initiated for elevated liver enzyme levels.

An observational study has found that patients with chronic liver disease (CLD) who used aspirin or another NSAID had a reduced risk of developing hepatocellular carcinoma and a reduced risk of dying from CLD.

We describe areas where major inroads were initially achieved by targeting angiogenesis and by unraveling pathways in the heterogeneous tumors of mesenchymal origin—spurred by the identification of c-Kit–activating mutations in GIST and the regressions that ensued when tumors harboring these mutations were exposed to the tyrosine kinase inhibitor imatinib (Gleevec).

A new study finds higher levels of vitamin E consumption could stave off liver cancer. The association held up for those who had a family history of liver disease and those who self-reported liver disease.


Subscribe to Liver, Gallbladder, and Biliary Tract Cancers on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.